Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida
Current Medical Research and Opinion. 2018 Jun;34(6):1099-1115
Clinical trials and real-world studies reported that canagliflozin (CANA) improved HbA1c, blood pressure (BP), and weight in patients with type 2 diabetes mellitus (T2DM). This study examines if previous results hold regionally and within specific patient sub-groups.
Adults with T2DM and ≥12 months of clinical activity before the first CANA prescription (index) were identified in electronicmedical records (January 1, 2012-February 15, 2017) from a network of hospitals in Florida. Quality measures were described at baseline and 3, 6, 9, and 12 months post-index. Selected thresholds were HbA1c < 7%, bp >< 140 90 mmhg, and weight loss ≥5%. sub-groups included patients ≥65 years old, with african american race, with cana dose increase, initiating cana in an endocrinology setting, and initiating cana in a primary care setting.> 140> 7%,>
Overall, 1,259 patients (mean age = 56.7 years; 51.2% female, 70.4% White) were identified. Among patients with a baseline HbA1c ≥ 7%, 16.1% had an HbA1c < 7% 3 months following cana initiation, and the mean hba1c decreased from 8.8% to 8.1%. among patients with a baseline systolic bp ≥140 mmhg or diastolic bp ≥ 90 mmhg, 59.3% attained a systolic bp >< 140 mmhg and 77.3% a diastolic bp >< 90 mmhg after 3 months. hba1c and bp responses were sustained through 12 months. the proportion of patients with a weight lossfrom baseline ≥5% increased from 17.0% at 3 months to 31.1% at 12 months. consistent trends were observed for all sub-groups.> 90 mmhg> 140 mmhg> 7%>
In CANA-treated patients and patient sub-groups from a network of Florida hospitals, improvements in quality measures and response durability were similar to clinical trials and other real-world studies.